Pharmaceuticals, Biotechnology & Life Sciences

Viatris Inc shares near 52‑week high as institutional buys and JPMorgan conference spotlight its growth strategy and pipeline, signaling potential upside for investors.

Merck plans large‑scale acquisitions to offset Keytruda’s exclusivity loss, boosting its biologics pipeline and long‑term growth prospects.

Liquidia Corp’s analyst upgrades boost targets to $49–$55, driven by strong Yutrepia sales, signaling a shift to a revenue‑driven growth narrative for investors.

Invivyd’s Q4 2025 results reveal a biotech firm advancing next‑gen COVID‑19 antibody NVD200, sparking investor interest and market volatility amid its $710M cap.

Harrow Inc. leads in ophthalmic drugs, treating conditions from dry eye to glaucoma, with a $1.73B market cap and detailed Nasdaq performance insights.

Formycon AG’s share sale by the Active Ownership Fund SICAV SIF SCS, led by supervisory‑board member Klaus Röhrig, signals a potential shift in investor confidence and may affect the biopharma firm’s stock and strategic outlook in the biosimilar mar…

BioAtla partners with GATC Health to advance Ozuriftamab Vedotin into a registration trial for second‑line OPSCC, marking a pivotal step toward new antibody‑based cancer therapy.

Explore how Anavex Life Sciences’ partnership with ACCESS‑AD could fast‑track blarcamesine—its sigma‑1 receptor drug—into a potential first‑in‑class Alzheimer’s therapy, boosting investor confidence and shaping future CNS precision medicine.

UniQure NV (QURE) – gene‑therapy stock with Overweight support, a robust pipeline, and legal scrutiny; is it a high‑reward opportunity or risk?

Discover how Sartorius AG’s new sustainability certification and bio‑circular product launch could reshape its ESG standing, investor confidence, and future growth prospects.